Shkreli controversially raised the price of the drug Daraprim, which is used to treat a potentially fatal parasitic infection, by 4,000%, from $13.50 to $750 per pill in 2015. In January, a federal judge banned him from the pharmaceutical industry for life.
Blue Cross and Blue Shield of Minnesota has filed a class-action lawsuit — on behalf of itself and insurers from 30-plus states — against Martin Shkreli and Vyera Pharmaceuticals. The suit alleges the defendants intentionally monopolized the market for Daraprim to raise the price of the drug by more than 4,000%.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
The drug, used to treat toxoplasmosis infection, became the subject of notoriety in 2015 when manufacturer Turing Pharmaceuticals, then led by Shkreli, raised the price from $13.50 to $750 per pill, making it a poster child for the issue of high drug prices.
The company is in trials for its drug, Firdapse, that treats LEMS. However, a generic form of that drug's been in use for decades.
During today’s congressional hearing on drug pricing, Rep. Jason Chaffetz (R-Utah) made his own case against the price gouging antics seen at Turing Pharmaceuticals. He pointed out a number of salary hikes seen last year among Turing’s top executives, as noted in documentation received by the House Oversight and Government Reform Committee in advance of the hearing. […]
Congressmen were up in arms over Martin Shkreli's disrespectful behavior - and that fueled their attacks against drug pricing in the pharmaceutical industry. Here are four of their most interesting rants.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Martin Shkreli Shkreli talks about cocaine in a new video railing against Wu Tang Clan member Ghostface Killah. Perhaps he should be talking about clozapine instead.
Martin Shkreli won't violate the terms of his bail when he travels to Washington to appear before a congressional committee on drug pricing, the U.S. DOJ writes.
Ron Tilles, the chairman of the board for Turing Pharmaceuticals, has stepped up to replace Martin Shkreli as CEO.
Martin Shkreli looked uncharacteristically somber during his perp walk on Thursday morning. Begs the question: Is this the end of Shkreli's ludicrous, smug antics? Nah.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
However, U.S. Attorney Robert Capers says the investigation doesn't involve Martin Shkreli's price hike of Daraprim, and he's "not aware of where he got the funds for the Wu Tang album."
Turing Pharmaceuticals CEO Martin Shkreli, vilified for hiking up the pricing of the drug Daraprim, is back in the news - for livestreaming the day-to-day activities of his life. It is not so riveting.
The day after news broke that Turing Pharmaceuticals' Daraprim has a new competitor on the market, CEO Martin Shkreli announced the company's gotten fast-track status for its experimental epilepsy drug.
San Diego's Imprimis Pharmaceuticals could give Martin Shkreli a run for his money - offering an alternative to the egregiously high cost Daraprim at $1 a pill.
Martin Shkreli attracted a legion of negative attention from the masses thanks to his drug price hikes - and less-than-winsome persona. But can we learn something from this?